We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-10.43%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$957M
AUM Growth
-$191M
Cap. Flow
-$30.2M
Cap. Flow %
-3.16%
Top 10 Hldgs %
64.82%
Holding
49
New
12
Increased
12
Reduced
7
Closed
13

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$59.6M
2
ABMD
Abiomed Inc
ABMD
+$35.9M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$32.6M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$30.7M
5
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$29.3M

Top Sells

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$69.6M
2
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$50.4M
3
DERM
Dermira, Inc.
DERM
+$39.7M
4
TGTX icon
TG Therapeutics
TGTX
+$36.4M
5
XLRN
Acceleron Pharma
XLRN
+$36.1M

Sector Composition

Rank Sector Weight
1 Healthcare 90.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
1
Acadia Pharmaceuticals
ACAD
$4.43B
$84.3M 8.81%
1,995,747
+745,747
+60% +$30.7M
ZYME icon
2
Zymeworks
ZYME
$1.61B
$82.5M 8.62%
2,324,688
+100,899
+5% +$4.13M
PTCT icon
3
PTC Therapeutics
PTCT
$5.64B
$78.7M 8.22%
1,763,387
+13,387
+0.8% +$674K
IOVA icon
4
Iovance Biotherapeutics
IOVA
$1.82B
$71.5M 7.47%
2,387,606
-2,627,569
-52% -$69.6M
CNST
5
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$62.2M 6.49%
1,977,502
+842,380
+74% +$29.3M
UTHR icon
6
United Therapeutics
UTHR
$25.8B
$52.7M 5.51%
556,252
+15,073
+3% +$1.43M
SAGE
7
DELISTED
Sage Therapeutics
SAGE
$52.4M 5.47%
1,824,479
+1,028,422
+129% +$59.6M
NXTC icon
8
NextCure
NXTC
$16.8M
$48.7M 5.09%
109,413
+14,864
+16% +$7.94M
XLRN
9
DELISTED
Acceleron Pharma
XLRN
$48.1M 5.03%
535,627
-464,373
-46% -$36.1M
GWPH
10
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$39.4M 4.12%
450,000
+308,317
+218% +$32.6M
BHVN
11
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$34M 3.56%
+1,000,000
New +$45.7M
ABMD
12
DELISTED
Abiomed Inc
ABMD
$31.4M 3.28%
+216,144
New +$35.9M
MNTA
13
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$26.6M 2.78%
979,400
-1,811,000
-65% -$50.4M
TGTX icon
14
TG Therapeutics
TGTX
$7.96B
$25.2M 2.63%
2,556,324
-2,878,459
-53% -$36.4M
MYOK
15
CALL
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$23.4M 2.45%
+500,000
New +$32M
PRTA icon
16
Prothena Corp
PRTA
$425M
$22.3M 2.33%
2,082,841
-18,100
-0.9% -$219K
BHVN
17
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$19.8M 2.07%
+581,905
New +$26.6M
MYOK
18
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$17.1M 1.78%
+364,163
New +$23.3M
ARNA
19
DELISTED
Arena Pharmaceuticals Inc
ARNA
$16.3M 1.7%
+387,499
New +$17.8M
ABEO icon
20
Abeona Therapeutics
ABEO
$366M
$15.1M 1.58%
288,520
– –
CCXI
21
DELISTED
ChemoCentryx, Inc.
CCXI
$14.4M 1.5%
+357,379
New +$15.2M
AXNX
22
DELISTED
Axonics, Inc. Common Stock
AXNX
$13.8M 1.44%
542,929
+76,422
+16% +$2.27M
MTEM
23
DELISTED
Molecular Templates, Inc.
MTEM
$11M 1.15%
55,000
– –
TGTX icon
24
CALL
TG Therapeutics
TGTX
$7.96B
$9.84M 1.03%
+1,000,000
New +$12.6M
TPST icon
25
Tempest Therapeutics
TPST
$13.7M
$9.13M 0.95%
8,871
– –
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2020 Portfolio in Review

As of Q1 2020, Great Point Partners held 49 positions worth $957M, down 17% from $1.15B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Great Point Partners withdrew a net $30.2M in Q1 2020, closing 13 positions and reducing 7 holdings. Its most notable exit was Dermira, Inc., an estimated $39.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Abiomed Inc worth $31.4M.

  • Great Point Partners's largest Q1 2020 buy was Abiomed Inc: 216,144 shares worth $31.4M.
  • Great Point Partners added most to Sage Therapeutics in Q1 2020, an estimated $59.6M increase.
  • Great Point Partners's biggest Q1 2020 reduction was Iovance Biotherapeutics, cutting an estimated $69.6M.
  • Great Point Partners fully exited Dermira, Inc. in Q1 2020, selling an estimated $39.7M.
  • Great Point Partners's ten largest holdings make up 65% of its $957M portfolio in Q1 2020.
  • Great Point Partners opened 12 new positions and closed 13 in Q1 2020.
  • Great Point Partners's portfolio value fell 17% quarter-over-quarter to $957M.

Based on Great Point Partners's 13F filing for Q1 2020, filed 15 May 2020.